BRAF and neoplasm: Sorafenib (BAY43-9006, Nexavar) is multikinase inhibitor with dual inhibitory activity against RAF/MEK/ERK (Raf-1, B-Raf) in the tumour cell and vascular growth factor inhibitor family (VEGFR1, VEGFR2) and platelets derived growth factor receptor (PDGFR, c-Kit) which promote tumour progression and angiogenesis.